Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Reda G Yousef"'
Autor:
Ibrahim H Eissa, Reda G Yousef, Eslam B Elkaeed, Aisha A Alsfouk, Dalal Z Husein, Ibrahim M Ibrahim, Hesham A El-Mahdy, Hazem Elkady, Ahmed M Metwaly
Publikováno v:
Evolutionary Bioinformatics, Vol 19 (2023)
The overexpression of the Epidermal Growth Factor Receptor (EGFR) marks it as a pivotal target in cancer treatment, with the aim of reducing its proliferation and inducing apoptosis. This study aimed at the CADD of a new apoptotic EGFR inhibitor. The
Externí odkaz:
https://doaj.org/article/646090e38afb4cf69efe8364aced2105
Autor:
Ibrahim H Eissa, Reda G Yousef, Eslam B Elkaeed, Aisha A Alsfouk, Dalal Z Husein, Ibrahim M Ibrahim, Mohamed S Alesawy, Hazem Elkady, Ahmed M Metwaly
Publikováno v:
PLoS ONE, Vol 18, Iss 3, p e0282586 (2023)
A new semisynthetic derivative of the natural alkaloid, theobromine, has been designed as a lead antiangiogenic compound targeting the EGFR protein. The designed compound is an (m-tolyl)acetamide theobromine derivative, (T-1-MTA). Molecular Docking s
Externí odkaz:
https://doaj.org/article/887e9078ecfd4e87a1d6ae8f6b4f76bc
Autor:
Reda G. Yousef, Alaa Elwan, Ibraheem M. M. Gobaara, Ahmed B. M. Mehany, Wagdy M. Eldehna, Souad A. El-Metwally, Bshra A. Alsfouk, Eslam B. Elkaeed, Ahmed M. Metwaly, Ibrahim H. Eissa
Publikováno v:
Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 37, Iss 1, Pp 2206-2222 (2022)
New nicotinamide derivatives 6, 7, 10, and 11 were designed and synthesised based on the essential features of the VEGFR-2 inhibitors. Compound 10 revealed the highest anti-proliferative activities with IC50 values of 15.4 and 9.8 µM against HCT-116
Externí odkaz:
https://doaj.org/article/c09df274b94249cb8a1c29016714c3fc
Autor:
Reda G. Yousef, Albaraa Ibrahim, Mohamed M. Khalifa, Wagdy M. Eldehna, Ibraheem M. M. Gobaara, Ahmed B. M. Mehany, Eslam B. Elkaeed, Aisha A. Alsfouk, Ahmed M. Metwaly, Ibrahim H. Eissa
Publikováno v:
Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 37, Iss 1, Pp 1389-1403 (2022)
A library of modified VEGFR-2 inhibitors was designed as VEGFR-2 inhibitors. Virtual screening was conducted for the hypothetical library using in silico docking, ADMET, and toxicity studies. Four compounds exhibited high in silico affinity against V
Externí odkaz:
https://doaj.org/article/8d0e025758924bbe9f7388baf0e479e8
Autor:
Reda G. Yousef, Hazem Elkady, Eslam B. Elkaeed, Ibraheem M. M. Gobaara, Hanan A. Al-ghulikah, Dalal Z. Husein, Ibrahim M. Ibrahim, Ahmed M. Metwaly, Ibrahim H. Eissa
Publikováno v:
Molecules, Vol 27, Iss 22, p 7719 (2022)
(E)-N-(3-(1-(2-(4-(2,2,2-Trifluoroacetamido)benzoyl)hydrazono)ethyl)phenyl)nicotinamide (compound 10) was designed as an antiangiogenic VEGFR-2 inhibitor with the essential pharmacophoric structural properties to interact with the catalytic pocket of
Externí odkaz:
https://doaj.org/article/8ffc0b98a2314df081995f65fd606add
Autor:
Eslam B. Elkaeed, Reda G. Yousef, Hazem Elkady, Aisha A. Alsfouk, Dalal Z. Husein, Ibrahim M. Ibrahim, Ahmed M. Metwaly, Ibrahim H. Eissa
Publikováno v:
Molecules, Vol 27, Iss 18, p 5859 (2022)
Based on the pharmacophoric features of EGFR inhibitors, a new semisynthetic theobromine-derived compound was designed to interact with the catalytic pocket of EGFR. Molecular docking against wild (EGFRWT; PDB: 4HJO) and mutant (EGFRT790M; PDB: 3W2O)
Externí odkaz:
https://doaj.org/article/e4fd8ccc6e174c779edf7e5934ff90af
Autor:
Eslam B. Elkaeed, Reda G. Yousef, Mohamed M. Khalifa, Albaraa Ibrahim, Ahmed B. M. Mehany, Ibraheem M. M. Gobaara, Bshra A. Alsfouk, Wagdy M. Eldehna, Ahmed M. Metwaly, Ibrahim H. Eissa, Mohamed Ayman El-Zahabi
Publikováno v:
Molecules, Vol 27, Iss 19, p 6203 (2022)
Four new nicotinamide-based derivatives were designed as antiangiogenic VEGFR-2 inhibitors. The congeners were synthesized possessing the pharmacophoric essential features to bind correctly with the VEGFR-2 active pocket. All members were evaluated f
Externí odkaz:
https://doaj.org/article/24f5a628f6624dcb95882eb504fbf8fc
Autor:
Eslam B. Elkaeed, Reda G. Yousef, Hazem Elkady, Ibraheem M. M. Gobaara, Bshra A. Alsfouk, Dalal Z. Husein, Ibrahim M. Ibrahim, Ahmed M. Metwaly, Ibrahim H. Eissa
Publikováno v:
Molecules, Vol 27, Iss 14, p 4606 (2022)
A nicotinamide-based derivative was designed as an antiproliferative VEGFR-2 inhibitor with the key pharmacophoric features needed to interact with the VEGFR-2 catalytic pocket. The ability of the designed congener ((E)-N-(4-(1-(2-(4-benzamidobenzoyl
Externí odkaz:
https://doaj.org/article/f53f93535d5c43129c331ed0d09af1b9
Autor:
Reda G. Yousef, Wagdy M. Eldehna, Alaa Elwan, Abdelaziz S. Abdelaziz, Ahmed B. M. Mehany, Ibraheem M. M. Gobaara, Bshra A. Alsfouk, Eslam B. Elkaeed, Ahmed M. Metwaly, Ibrahim H. Eissa
Publikováno v:
Molecules, Vol 27, Iss 13, p 4079 (2022)
VEGFR-2, the subtype receptor tyrosine kinase (RTK) responsible for angiogenesis, is expressed in various cancer cells. Thus, VEGFER-2 inhibition is an efficient approach for the discovery of new anticancer agents. Accordingly, a new set of nicotinam
Externí odkaz:
https://doaj.org/article/08d1daded8fe4409a86a1ceeb66c0680
Autor:
Ibrahim H. Eissa, Reda G. Yousef, Hazem Elkady, Aisha A. Alsfouk, Bshra A. Alsfouk, Dalal Z. Husein, Ibrahim M. Ibrahim, Eslam B. Elkaeed, Ahmed M. Metwaly
Publikováno v:
Life; Volume 13; Issue 1; Pages: 191
A new lead compound has been designed as an antiangiogenic EGFR inhibitor that has the pharmacophoric characteristics to bind with the catalytic pocket of EGFR protein. The designed lead compound is a (para-chloro)acetamide derivative of the alkaloid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e28f4de422f56e94355c9b6817c62b1d